Assembly Biosciences Near Breakout; Key Clinical Trials in Focus
AI Prediction of Assembly Biosciences, Inc (ASMB)
Assembly Biosciences, a clinical-stage biotech company focusing on hepatitis B cures, has shown promising developments in its drug pipeline and strategic collaborations. Given the upcoming clinical trial results and potential regulatory milestones, investors may find significant opportunities for growth.
ASMB Report Information
Prediction Date2025-07-03 06:17:46
Close @ Prediction$18.14
Mkt Cap130m
IPO Date2010-12-17
AI-derived Information
Recent News for ASMB
- Aug 11 — Assembly Bios herpes drug shows 94% viral shedding (Clinical Trials Arena)
- Aug 8 — Assembly Biosciences Announces Pricing of $175 Million in Equity Financings (GlobeNewswire)
- Aug 8 — Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes (GlobeNewswire)
- Aug 6 — Assembly Biosciences: Q2 Earnings Snapshot (Associated Press Finance)
- Aug 6 — Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus (GlobeNewswire)
- Aug 6 — Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates (GlobeNewswire)
- Jul 26 — Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop (GlobeNewswire)
- Jul 24 — Assembly Bio's (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial (Insider Monkey)
- Jul 2 — Assembly Biosciences, Inc. (ASMB) Announces Key Leadership and Plan Changes (Insider Monkey)
- Jul 1 — First subject dosed in Assembly Biosciences study for genital herpes (Clinical Trials Arena)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.